This reduction in Ki67 expression was accompanied by a significant decrease in HER2 levels in the tumor tissue (a 1.7-fold decrease compared to the control), suggesting that the overall anti-tumor activity of compound 10 is primarily due to its capacity to inhibit HER2 expression (Figure 6G, left panel). This evidence concerns the gene ERBB2 and neoplasm.